Verici Dx plc (LON:VRCI – Get Free Report)’s stock price shot up 31.8% during trading on Thursday . The company traded as high as GBX 3.63 ($0.05) and last traded at GBX 3.63 ($0.05). 959,982 shares traded hands during mid-day trading, an increase of 65% from the average session volume of 581,209 shares. The stock had previously closed at GBX 2.75 ($0.04).
Verici Dx Price Performance
The company has a quick ratio of 8.49, a current ratio of 4.54 and a debt-to-equity ratio of 4.64. The company has a market cap of £8.62 million, a PE ratio of -1.65 and a beta of 1.59. The stock has a 50-day simple moving average of GBX 3.77 and a 200 day simple moving average of GBX 4.33.
Verici Dx Company Profile
Verici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes. The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage.
Read More
- Five stocks we like better than Verici Dx
- 3 Grocery Stocks That Are Proving They Are Still Essential
- These 4 Tech ETFs Just Hit 50-Day Lows—Time to Buy?
- There Are Different Types of Stock To Invest In
- 3 Stocks to Buy While Others Stay on the Sidelines
- Compound Interest and Why It Matters When Investing
- MarketBeat Week in Review – 03/03 – 03/07
Receive News & Ratings for Verici Dx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verici Dx and related companies with MarketBeat.com's FREE daily email newsletter.
